Drug Type Antibody fusion proteins |
Synonyms Claseprubart and TACI bifunctional fusion protein, DNTH 312, DNTH312 |
Target |
Action inhibitors |
Mechanism C1S inhibitors(Complement C1s inhibitors), TNFRSF13B inhibitors(Tumor necrosis factor receptor superfamily member 13B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States | 01 Aug 2026 |






